Pfizer Files Lawsuit Against Novo: Alleges Competitor Engaged in Antitrust Scheme to Dominate Obesity Market
- Pfizer sues Novo Nordisk and Metsera in Delaware courts, alleging anticompetitive tactics to block its $7.2B obesity drug acquisition. - Novo's $8.5B superior bid for Metsera's GLP-1 pipeline—valued at $5B peak sales—triggers legal claims over regulatory bypass and contract violations. - Pfizer leverages early FTC approval for its deal, seeking court orders to force a November 13 shareholder vote amid patent expiration threats. - The dispute highlights $150B obesity market stakes, with Novo defending its
Pfizer Inc. (PFE) has intensified its legal efforts to maintain its stake in the obesity-focused biotech company
The dispute revolves around Metsera’s pipeline of experimental GLP-1 treatments, which feature a once-monthly injectable that has demonstrated an average 14% weight reduction in clinical trials, as well as a chemically stabilized oral version. Analysts estimate these products could achieve peak annual sales of $5 billion, according to
Pfizer’s legal argument is based on its regulatory advantage: the FTC ended its Hart-Scott-Rodino review early on October 31, ahead of the November 7 deadline, as noted by
This legal showdown highlights the growing rivalry in the obesity medication industry, which analysts expect to reach $150 billion in value by 2030. Novo, facing increased competition from Eli Lilly’s tirzepatide, is working to strengthen its drug portfolio before semaglutide patents expire. Meanwhile, Pfizer is attempting to gain entry into the sector after discontinuing its oral obesity drug candidate, danuglipron, as reported by
Metsera’s investors, led by Population Health Partners and ARCH Venture Partners, are under investigation for possible collusion with Novo, according to
With Pfizer facing a November 5 deadline to respond to Novo’s proposal and a shareholder vote approaching, Delaware courts are poised to decide whether competitive issues or contractual commitments will take precedence in this major pharmaceutical dispute.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP News Today: Ripple's Efforts with Institutions Meet XRP Price Fluctuations Amid Growing ETF Anticipation
- Ripple accelerates institutional finance push via XRP ETF plans, strategic acquisitions, and product innovations like Ripple Prime's cross-margining platform. - The firm secures 75+ global licenses and partners with major banks, aligning with growing speculation about SEC approval for Grayscale's GXRP ETF by late 2025. - XRP's $2.27 price and $170B market cap contrast with Ripple's infrastructure growth, as traders weigh regulatory risks against potential ETF-driven institutional demand.

Advisers Utilize Adaptive ETF Strategies to Address Volatility in Emerging Markets
- FPI launches FlexDirex, a dynamic ETF platform using leveraged/inverse strategies to manage emerging market volatility for investors. - Allspring's Emerging Markets fund targets resilient companies like TSMC and Tencent, outperforming benchmarks through active management. - Experts emphasize systematic risk mitigation and long-term investing over market timing to navigate geopolitical/economic uncertainties. - Dynamic tools and active strategies are expanding in emerging markets, prioritizing disciplined

DOGE drops 5.11% as large holders offload 1 billion tokens, putting the $0.15 support level at risk
- Dogecoin (DOGE) fell 5.11% to $0.16013 on Nov 4, 2025, with 13.04% weekly and 14.8% monthly declines. - Whale holders dumped 1 billion DOGE in a week, pushing price below $0.18—a key psychological threshold. - On-chain data and order-book imbalances confirm coordinated offloading, raising risks for $0.15 support and retail buyers. - Backtests show "-10% in a day" patterns yield no reliable edge, with 30-day returns underperforming by 9 percentage points.
Bitcoin Updates Today: Bitcoin-Backed Borrowing: Companies Reduce Debts Yet Confront Unpredictable Price Swings
- Sequans Communications sold 970 BTC ($94.5M) to cut debt, reducing liabilities by 50% and lowering its debt-to-NAV ratio to 39%. - Hong Kong firms like Meitu are increasingly using Bitcoin as a strategic reserve amid relaxed crypto regulations and global competition. - Despite the sale, Sequans' stock fell 82% YTD, highlighting market skepticism toward Bitcoin-focused equities amid price volatility. - The move underscores risks of Bitcoin treasury strategies, with Sequans' $2.4B market cap trading below
